文献速递肾癌与肾肿瘤

KEYNOTE-426研究:帕博利珠单抗联合阿昔替尼对比舒尼替尼治疗晚期肾细胞癌的健康相关生活质量分析

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2022-07-15

KEYNOTE-426三期试验中,861例晚期肾细胞癌患者随机接受帕博利珠单抗联合阿昔替尼(n=432)或舒尼替尼(n=429)治疗。生活质量分析显示,两组在FKSI-DRS、QLQ-C30和EQ-5D VAS的总体改善率无差异或联合组更优,但FKSI-DRS的至确认恶化时间舒尼替尼组更优(HR 1.4;95%CI 1.1-1.7)。

要点

  • 联合组与舒尼替尼组总体生活质量改善率无差异或联合组更优。
  • QLQ-C30至确认恶化时间两组无差异(HR 1.0;95%CI 0.82-1.3)。
  • FKSI-DRS至确认恶化时间舒尼替尼组更优(HR 1.4;95%CI 1.1-1.7)。

核心结论

  • 总体而言,患者报告结局量表显示帕博利珠单抗联合阿昔替尼组与舒尼替尼组结果无差异,但FKSI-DRS的至确认恶化时间除外。

研究设计与样本

  • 三期KEYNOTE-426(NCT02853331)试验,861例晚期肾细胞癌患者随机接受帕博利珠单抗联合阿昔替尼(n=432)或舒尼替尼(n=429)治疗。
  • 生活质量数据可评估者:帕博利珠单抗联合阿昔替尼组429例,舒尼替尼组423例。
  • 使用EORTC QLQ-C30、EQ-5D视觉模拟评分量表(VAS)和FKSI-DRS问卷测量健康相关生活质量终点。

主要发现

  • FKSI-DRS总体改善率:帕博利珠单抗联合阿昔替尼组较舒尼替尼组-0.79%(95%CI -7.2至5.6)。
  • QLQ-C30总体改善率:帕博利珠单抗联合阿昔替尼组较舒尼替尼组7.5%(95%CI 1.0-14)。
  • EQ-5D VAS总体改善率:帕博利珠单抗联合阿昔替尼组较舒尼替尼组9.9%(95%CI 3.2-17)。
  • QLQ-C30至确认恶化时间HR 1.0(95%CI 0.82-1.3),至首次恶化时间HR 0.82(95%CI 0.69-0.97),两组无差异。
  • EQ-5D VAS至确认恶化时间HR 1.1(95%CI 0.87-1.3),至首次恶化时间HR 0.98(95%CI 0.83-1.2),两组无差异。

局限性

  • 舒尼替尼组患者在停药期间进行评估,可能低估了舒尼替尼对健康相关生活质量的负面影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 KEYNOTE-426 (NCT02853331) trial, pembrolizumab + axitinib demonstrated improvement in overall survival, progression-free survival, and objective response rate over sunitinib monotherapy for advanced renal cell carcinoma (RCC). OBJECTIVE: To evaluate health-related quality of life (HRQoL) in KEYNOTE-426. DESIGN, SETTING, AND PARTICIPANTS: A total of 861 patients were randomly assigned to receive pembrolizumab + axitinib (n = 432) or sunitinib (n = 429). HRQoL data were available for 429 patients treated with pembrolizumab + axitinib and 423 patients treated with sunitinib. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: HRQoL end points were measured using the European Organisation for the Research and Treatment of Cancer Core (EORTC) Quality of Life Questionnaire (QLQ-C30), EQ-5D visual analog rating scale (VAS), and Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index-Disease-Related Symptoms (FKSI-DRS) questionnaires. RESULTS AND LIMITATIONS: Better or not different overall improvement rates from baseline between pembrolizumab + axitinib and sunitinib were observed for the FKSI-DRS (-0.79% improvement vs sunitinib; 95% confidence interval [CI] -7.2 to 5.6), QLQ-C30 (7.5% improvement vs sunitinib; 95% CI 1.0-14), and EQ-5D VAS (9.9% improvement vs sunitinib; 95% CI 3.2-17). For time to confirmed deterioration (TTcD) and time to first deterioration (TTfD), no differences were observed between arms for the QLQ-C30 (TTcD hazard ratio [HR] 1.0; 95% CI 0.82-1.3; TTfD HR 0.82; 95% CI 0.69-0.97) and EQ-5D VAS (TTcD HR 1.1; 95% CI 0.87-1.3; TTfD HR 0.98; 95% CI 0.83-1.2). TTfD was not different between treatment arms (HR 1.1; 95% CI 0.95-1.3) for the FKSI-DRS, but TTcD favored sunitinib (HR 1.4; 95% CI 1.1-1.7). Patients were assessed during the off-treatment period for sunitinib, which may have underestimated the negative impact of sunitinib on HRQoL. CONCLUSIONS: Overall, patient-reported outcome scales showed that results between the pembrolizumab + axitinib and sunitinib arms were not different, with the exception of TTcD by the FKSI-DRS. PATIENT SUMMARY: Compared with sunitinib, pembrolizumab + axitinib delays disease progression and extends survival, while HRQoL outcomes were not different between groups.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bedke J, Rini BI, Plimack ER, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022. PMID: 35843776. doi:10.1016/j.eururo.2022.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。